MLYS.O Share Price Today: Live Updates & Key Insights

MLYS.O share price today is $24.3, up 3.39%. The stock opened at $23.06 against the previous close of $23.28, with an intraday high of $24.34 and low of $22.64.

MLYS.O Share Price Chart

MLYS.O

us-stock
To Invest in {{usstockname}}
us-stock

MLYS.O Share Price Performance

$24.3 0.0339(3.39%) MLYS at 23 Mar 2026 02:18 PM Biotechnology
Lowest Today 22.64
Highest Today 24.34
Today’s Open 23.06
Prev. Close 23.28
52 Week High 47.65
52 Week Low 10.44
Day’s Range: Low 22.64 High 24.34
52-Week Range: Low 10.44 High 47.65
1 day return -
1 Week return -6.34
1 month return -16.77
3 month return -35.94
6 month return -37.96
1 year return +48.35
3 year return +66.86
5 year return -
10 year return -

MLYS.O Institutional Holdings

MLYS.O Market Status

Strong Buy: 6

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

MLYS.O Fundamentals

Market Cap 1983.36 M

PB Ratio 2.9637

PE Ratio 0.0

Enterprise Value 1261.62 M

Total Assets 661.81 M

Volume 2894909

MLYS.O Company Financials

Annual Revenue FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-177810000 -177.8M, FY23:-56582000 -56.6M, FY22:-29799000 -29.8M, FY21:-19408000 -19.4M, FY20:-3426000 -3.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q3/2025:-15000 -0.0M, Q2/2025:-16000 -0.0M, Q1/2025:-15000 -0.0M, Q4/2024:null 0.0M, Q3/2024:null 0.0M

Quarterly Net worth Q3/2025:-36932000 -36.9M, Q2/2025:-43274000 -43.3M, Q1/2025:-42211000 -42.2M, Q4/2024:-48946000 -48.9M, Q3/2024:-56342000 -56.3M

About MLYS.O & investment objective

Company Information Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Organisation Biotechnology

Employees 76

Industry Biotechnology

CEO Mr. Jon Congleton

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

MLYS.O FAQs

What is the share price of MLYS.O today?

The current share price of MLYS.O is $24.3.

Can I buy MLYS.O shares in India?

Yes, Indian investors can buy MLYS.O shares by opening an international trading and demat account with Motilal Oswal.

How to buy MLYS.O shares in India?

You can easily invest in MLYS.O shares from India by:

Can I buy fractional shares of MLYS.O?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of MLYS.O?

MLYS.O has a market cap of $1983.36 M.

In which sector does MLYS.O belong?

MLYS.O operates in the Biotechnology sector.

What documents are required to invest in MLYS.O stocks?

To invest, you typically need:

What is the PE and PB ratio of MLYS.O?

The PE ratio of MLYS.O is N/A and the PB ratio is 2.96.